

data entry elements to those required by the committee. With this decision, activities at the local or headquarters level should be able to develop electronic versions which meet the committee's requirements. This

guideline controls the "image" or required fields but not the actual data entered into the field.

**SUMMARY:** With GSA's approval, the Interagency Committee of Medical Records (ICMR) eliminated the

requirement that every electronic version of a medical Standard/Optional form be reviewed and granted an exception. The following fields must appear on the electronic version of the following form:

#### ELECTRONIC ELEMENTS FOR SF 512

Item	Placement <sup>1</sup>
(Plotting Chart (Title) ..... (Standard Form 512 (Rev. 3/1994) (Form ID) .....	Top of form. Bottom right corner of form.
Data Entry Fields Title of Purpose of Graph Data (Allow for at least 14 entries) Time (Allow for at least 14 entries) Graphic (Allow for at least 14 plots)	
Patient Information (Text) ..... Last Name First Name Middle Name Rank Rate Hospital or Medical Facility	Above below listed items.
Register No. Ward No.	

<sup>1</sup> If no specific placement, data element may be in any order.

**FOR FURTHER INFORMATION CONTACT:** CDR Katherine Ciacco Palatianos, Indian Health Service, Department of Health and Human Services, 5600 Fishers Lane, Room 6A-55, Rockville, MD 20857 or e-mail at [kciacco@hge.ihs.gov](mailto:kciacco@hge.ihs.gov).

**DATES:** Effective March 8, 2002.

Dated: February 12, 2002.

**Katherine Ciacco Palatianos,**  
*Chairperson, Interagency Committee on Medical Records.*

[FR Doc. 02-5545 Filed 3-7-02; 8:45 am]

**BILLING CODE 6820-34-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Agency Information Collection Activities: Submission for OMB Review; Comment Request

The Department of Health and Human Services, Office of the Secretary publishes a list of information collections it has submitted to the Office of Management and Budget (OMB) for clearance in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35) and 5 CFR 1320.5. The following are those information collections recently submitted to OMB.

1. Wave 3 Survey of Youth for the Federal Evaluation of Initiatives Funded Under Section 510 of the Maternal and Child Health Block Grant Programs—The Personal Responsibility and Work Opportunity Reconciliation Act

established Section 510 of the Maternal and Child Health Block Grant Program, the purpose of which is to support state efforts supporting abstinence only education. This data collection is needed to fulfill the requirements for a Congressionally mandated evaluation of the program. *Respondents:* Individuals; *Number of Respondents:* 2,872; *Average Burden per Response:* 5 hours; *Total Burden:* 1,436 hours. *OMB Desk Officer:* Allison Herron Eydt.

Copies of the information collection packages listed above can be obtained by calling the OS Reports Clearance Officer on (202) 690-6207. Written comments and recommendations for the proposed information collection should be sent directly to the OMB desk officer designated above at the following address:

Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, 725 17th Street NW., Washington, DC 20503.

Comments may also be sent to Cynthia Agens Bauer, OS Reports Clearance Officer, Room 503H, Humphrey Building, 200 Independence Avenue SW., Washington DC 20201. Written comments should be received within 30 days of this notice.

Dated: February 26, 2002.

**Kerry Weems,**

*Acting, Deputy Assistant Secretary, Budget.*

[FR Doc. 02-5510 Filed 3-7-02; 8:45 am]

**BILLING CODE 4154-05-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Meeting of the Advisory Committee on Minority Health

**AGENCY:** Department of Health and Human Services, Office of the Secretary, Office of Public Health and Science, Office of Minority Health.

**ACTION:** Notice of meeting.

**SUMMARY:** The Advisory Committee on Minority Health will meet to discuss racial and ethnic disparities in health, as well as other related issues. The meeting is open to the public. There will be an opportunity for public comment which will be limited to five minutes per speaker. Individuals who would like to submit written statements should mail or fax their comments to the Office of Minority Health at least two business days prior to the meeting.

**DATES:** The Advisory Committee on Minority Health will meet on Thursday, March 21, 2002 from 9 a.m. to 5 p.m., and Friday, March 22, 2000 from 8:30 a.m. to 12 noon.

**ADDRESSES:** The meeting will be held at the Hamilton Crowne Plaza, Oasis Room, 1001 14th Street, NW., Washington, DC.

**FOR FURTHER INFORMATION CONTACT:** Ms. Sheila P. Merriweather, Office of Minority Health, Rockwall Building, 5515 Security Lane, Suite 1000, Rockville, MD 20852. Phone: 301-443-9923, Fax: 301-443-8280.

Dated: March 4, 2002.

**Nathan Stinson, Jr.,**

*Deputy Assistant Secretary for Minority Health.*

[FR Doc. 02-5511 Filed 3-7-02; 8:45 am]

BILLING CODE 4150-29-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Prospective Grant of Exclusive License: Vaccines and Diagnostic Tests for Cat Scratch Fever

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patent and patent applications referred to below to Intervet Inc. (Intervet) having a place of business in Millsboro, Delaware. The patent rights in these inventions have been assigned to the government of the United States of America. The patent and patent applications to be licensed are:

*Title:* Methods and compositions for diagnosing cat scratch disease and bacillary angiomatosis caused by *Rochalimaea henselae*.

U.S. Patent Application Serial No. 07/822,539.

*Filing Date:* 01/17/92.

*Domestic Status:* Patent No.:

5,399,485.

*Issue Date:* 03/21/95.

*Title:* Methods and compositions for diagnosing *Rochalimaea henselae* and *Rochalimaea quintana* infection.

U.S. Patent Application Serial No. 08/245,294.

*Filing Date:* 05/18/94.

*Domestic Status:* Patent No.:

5,644,047.

*Issue Date:* 07/01/97.

*Title:* Nucleic acids specific for *Rochalimaea quintana*.

U.S. Patent Application Serial No. 08/474,499.

*Filing Date:* 06/07/95.

*Domestic Status:* Patent No.:

5,693,776.

*Issue Date:* 12/02/97.

*Title:* Nucleic acids of *Rochalimaea henselae* and methods and compositions

for diagnosing *Rochalimaea henselae* and *Rochalimaea quintana* infection.

U.S. Patent Application Serial No. 08/307,279.

*Filing Date:* 09/16/94.

*Domestic Status:* Patent No.:

5,736,347.

*Issue Date:* 04/07/98.

*Title:* Composition to protect a mammal against *Bartonella henselae* infection.

U.S. Patent Application Serial No. 08/922,970.

*Filing Date:* 09/03/97.

*Domestic Status:* Patent No.:

5,958,414.

*Issue Date:* 09/28/99.

*Title:* Methods and Compositions for Diagnosing *Rochalimaea Henselae* and *Rochalimaea Quintana* Infection.

U.S. Patent Application Serial No. 08/472,904.

*Filing Date:* 06/07/95.

*Title:* Nucleic acids of *Rochalimaea henselae* and compositions for diagnosing *Rochalimaea henselae* and *Rochalimaea quintana* infection.

U.S. Patent Application Serial No. 08/480,849.

*Filing Date:* 06/07/95.

*Title:* Methods and Compositions for Diagnosing *Rochalimaea Henselae* and *Rochalimaea Quintana* Infection.

U.S. Patent Application Serial No. 08/472,934.

*Filing Date:* 06/07/95.

*Title:* Nucleic Acids of *Rochalimaea Henselae* and Compositions for Diagnosing *Rochalimaea Henselae* and *Rochalimaea Quintana* Infection.

U.S. Patent Application Serial No. 09/525,310.

*Filing Date:* 03/14/00.

*Title:* Nucleic acids of *Rochalimaea henselae* and compositions for diagnosing *Rochalimaea henselae* and *Rochalimaea quintana* infection.

U.S. Patent Application Serial No. 09/752,385.

*Filing Date:* 12/29/00.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

Cat scratch fever or bacillary angiomatosis is a bacterial disease transmitted via a cat scratch or bite. A previously unidentified, pathogenic species of *Bartonella* (formerly *Rochalimaea*), *B. henselae*, has been identified as the primary causative agent. A related species, *B. quintana*, may also produce illness in immunocompromised individuals. This invention identifies immunogenic peptides useful for identification of *B. henselae* and diagnosis of bacillary angiomatosis and a method of vaccinating against bacillary angiomatosis.

**ADDRESSES:** Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to Andrew Watkins, Director, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610; facsimile: (770) 488-8615. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by CDC within sixty days of this notice will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. A signed Confidential Disclosure Agreement will be required to receive a copy of any pending patent application.

Dated: March 4, 2002.

**Joseph R. Carter,**

*Associate Director for Management and Operations, Centers for Disease Control and Prevention.*

[FR Doc. 02-5567 Filed 3-7-02; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Prospective Grant of Exclusive License: Growing *Ehrlichia* Species in a Continuous Cell Line

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (HHS), is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patent and patent applications referred to below to Intervet Inc. (Intervet) having a place of business in Millsboro, Delaware. The patent rights in these inventions have been assigned to the government of the United States of America. The patent and patent applications to be licensed are: